A comprehensive view of Weight Management Products. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.
Amgen testing injectable weight loss drug MariTide that offers the potential of monthly administration; the drug appears promising in early trials in a market forecast to be worth up to US$100.0B by the end of the decade
Published:
March 25, 2024
by Baystreet US News Alerts
|
Morningstar assigns Eli Lilly with US$500 fair value estimate, sees its competitive advantages lasting at least 20 years; with supply of Mounjaro/Zepbound expected to rise at least 50% in 2024, robust growth looks likely given capacity-constrained market
Published:
March 19, 2024
by Clayton News Daily (Jonesboro, GA)
|
Moody's expects GLP-1 drugs from Eli Lilly and Novo Nordisk to power pharmaceutical industry's earnings growth over next 12-18 months; analyst upgrades industry's outlook to positive from stable, forecasts 4%-6% overall earnings growth over the period
Published:
March 18, 2024
by FiercePharma
|
Capital Economics: Weight-loss drugs like Ozempic could boost global economy and lead to game-changing GDP boost by improving labor market activity, having healthier populations; nations with high obesity rates such as US and Mexico have most to gain
Published:
March 15, 2024
by Business Insider
|
Bank of America forecasts rise in weight-loss drug use from 1% of US adults currently to 15% by 2035, and investors are already pricing in growth for shares of Novo Nordisk, Eli Lilly; analyst lists 16 global companies producing or developing such drugs
Published:
March 07, 2024
by Business Insider
|
Ask us about our Tissue & Hygiene market view